{"disease":{"id":"attr-amyloidosis-with-cardiomyopathy","name":"attr amyloidosis with cardiomyopathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06836011","title":"A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT05505838","title":"Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}